For the quarter ending 2026-03-31, CTOR made $1,667,298 in revenue. -$26,609,695 in net income. Net profit margin of -1595.98%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 1,667,298 | 3,944,111 | - | 0 |
| Cost of revenues | 328,878 | 789,208 | - | - |
| Gross profit | 1,338,420 | 3,154,903 | - | - |
| Research and development | 1,079,354 | 1,018,352 | 1,076,136 | 938,277 |
| Amortization of in-process research and development | 1,720,312 | 573,438 | - | - |
| Revenues | - | - | - | 0 |
| General and administrative | 23,625,639 | 2,859,339 | 1,337,244 | 1,881,447 |
| Stock-based compensation general and administrative | 3,526,710 | 3,956,050 | 2,298,132 | 2,125,237 |
| Total operating expenses | 29,952,015 | 8,407,179 | 4,711,512 | 4,944,961 |
| Operating loss | -28,613,595 | -5,252,276 | -4,687,001.25* | -4,944,961 |
| Interest income | 43,721 | 28,288 | 9,093.25* | - |
| Gain on sale of new jersey net operating losses | 1,762,000 | - | - | - |
| Interest expense | 33,031 | 45,841 | 54,508* | 160,755 |
| Total other income, net | 1,772,690 | -17,553 | -45,414.75* | - |
| Loss before income taxes | -26,840,905 | -5,269,829 | -4,732,416 | -5,105,716 |
| Income tax expense (benefit) | -231,210 | 264,240 | 264,240 | 264,240 |
| Net loss | -26,609,695 | -5,534,069 | -4,996,656 | -5,369,956 |
| Basic EPS | -0.27 | -0.06 | -0.064 | -0.08 |
| Diluted EPS | -0.27 | -0.06 | -0.064 | -0.08 |
| Basic Average Shares | 100,027,204 | 87,462,385 | 78,414,670 | 71,552,402 |
| Diluted Average Shares | 100,027,204 | 87,462,385 | 78,414,670 | 71,552,402 |
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)